
And so, another working week will soon come to an end. Not a moment too soon, yes? For those who think this may sound premature, there is a holiday tomorrow on this side of the pond, so we are getting a head start on our weekend daydreaming. Our agenda is rather modest, given the circumstances. We do hope to hang with a couple of the short people, promenade with our energetic mascot and catch up on our reading. And what about you? This is a fine time to enjoy the outdoors. You could also putter around your castle. Or reach out to someone feeling isolated. Well, whatever you do, have a grand time. Enjoy, but be safe and wear a mask. This virus will not just disappear. See you soon…
Top Trump administration health officials are seeking to reassure the public that any potential Covid-19 vaccine will only be approved if it is safe and that the fast-track process will not be influenced by political pressure, The Hill reports. To assuage some of that concern, the agency released a guidance that outlines conditions for approving a vaccine. Those include requiring any vaccine to be at least 50% more effective than a placebo in preventing the disease.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.